Variable | All | Cardiovascular events | p valuea | |
---|---|---|---|---|
Present | Absent | |||
n | 333 | 31 | 302 | Â |
Age, years | 66 ± 11 | 68 ± 10 | 66 ± 11 | 0.235 |
Male sex | 211 (63) | 21 (68) | 190 (63) | 0.595 |
Body mass index, kg/m2 | 25 ± 5 | 25 ± 5 | 25 ± 4 | 0.991 |
Hypertension | 229 (69) | 21 (68) | 208 (69) | 0.897 |
Dyslipidemia | 219 (66) | 20 (65) | 199 (66) | 0.878 |
Current Smoker | 76 (23) | 9 (29) | 67 (22) | 0.387 |
Obesityb | 141 (42) | 12 (39) | 129 (43) | 0.667 |
β-blocker | 63 (19) | 3 (10) | 60 (20) | 0.168 |
Calcium channel blocker | 125 (38) | 13 (42) | 112 (37) | 0.595 |
ACE-I or ARB | 156 (47) | 14 (45) | 142 (47) | 0.843 |
Statin | 152 (46) | 11 (36) | 141 (47) | 0.233 |
Insulin therapy | 84 (25) | 7 (23) | 77 (26) | 0.722 |
Oral antihyperglycemic drugs | 184 (55) | 16 (52) | 168 (56) | 0.668 |
Metformin | 62 (19) | 3 (10) | 59 (20) | 0.179 |
Alpha glucosidase inhibitor | 52 (16) | 2 (7) | 50 (17) | 0.140 |
DPP4 inhibitor | 119 (36) | 12 (39) | 107 (35) | 0.717 |
eGFR, mL/min/1.73 m2 | 68 ± 19 | 69 ± 21 | 68 ± 18 | 0.672 |
Total cholesterol, mg/dL | 182 ± 32 | 190 ± 34 | 181 ± 32 | 0.145 |
LDL-cholesterol, mg/dL | 107 ± 28 | 120 ± 35 | 106 ± 27 | 0.013 |
HDL-cholesterol, mg/dL | 54 ± 17 | 53 ± 19 | 54 ± 16 | 0.666 |
Triglyceride, mg/dL | 115 (85, 169) | 114 (86, 169) | 116 (84, 169) | 0.859 |
HbA1c, % | 7.4 ± 1.5 | 7.5 ± 1.2 | 7.4 ± 1.5 | 0.703 |
CACS | 107 (2, 459) | 298 (106, 998) | 92 (0, 408) | 0.003 |
Pericardial fat volume, mL | 129 ± 53 | 133 ± 50 | 129 ± 54 | 0.633 |
LAD-PCAT attenuation, HU | − 70.6 ± 6.1 | − 68.5 ± 6.5 | − 70.8 ± 6.1 | 0.045 |
RCA-PCAT attenuation, HU | − 68.0 ± 6.9 | − 66.0 ± 8.2 | − 68.3 ± 6.7 | 0.089 |
Significant stenosis | 135 (41) | 22 (71) | 113 (37) | < 0.001 |
High-risk plaque | 81 (24) | 14 (45) | 67 (22) | 0.005 |
Suita score | 51 ± 10 | 55 ± 7 | 51 ± 11 | 0.001 |